{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:54:41Z","timestamp":1791248081607,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wuhan Medical Research Project","award":["WX20B09"],"award-info":[{"award-number":["WX20B09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Henagliflozin has demonstrated favorable glycemic and metabolic effects in phase III trials. However, real-world evidence regarding its impact on cardiac structure\u2014particularly left ventricular mass index (LVMI)\u2014in patients with type 2 diabetes mellitus (T2DM) and concomitant hypertension remains lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this single-center, retrospective cohort study, 183 patients with T2DM and hypertension were enrolled. After 1:1 propensity score matching, 132 patients (henagliflozin group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200966; control group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200966) were included in the primary analysis. The henagliflozin group received henagliflozin 10\u00a0mg once daily added to standard-of-care therapy, whereas the control group received standard therapy alone. The primary outcome was the change in LVMI from baseline to 6\u00a0months. Secondary outcomes included changes in other echocardiographic parameters (LVEF, E\/e\u2032, left atrial diameter, LVEDd, IVSd, LVPWT), glycemic indices (FPG, HbA1c), blood pressure, body mass index (BMI), inflammatory markers, and renal function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 6\u00a0months, LVMI decreased in the henagliflozin group (from 87.90\u2009\u00b1\u200918.32 to 85.28\u2009\u00b1\u200918.20\u00a0g\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; mean change \u2212\u20092.62\u2009\u00b1\u200913.00\u00a0g\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) but increased in the control group (from 83.46\u2009\u00b1\u200918.22 to 87.81\u2009\u00b1\u200916.53\u00a0g\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; mean change +\u20094.35\u2009\u00b1\u200915.88\u00a0g\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; between-group\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.007). Additionally, henagliflozin treatment was associated with significant reductions in left atrial diameter (between-group\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.035), E\/e\u2032 ratio (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.044), interventricular septal thickness (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.030), and left ventricular posterior wall thickness (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.018), as well as a modest increase in LVEF (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.045). Compared with the control group, the henagliflozin group also exhibited greater reductions in fasting plasma glucose (\u2212\u20090.97 vs.\u2009+\u20090.16\u00a0mmol\/L;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.037), HbA1c (\u2212\u20090.42% vs.\u2009+\u20090.04%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.021), systolic blood pressure (\u2212\u20099.45 vs. \u2212\u20091.95\u00a0mmHg;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023), diastolic blood pressure (\u2212\u20093.38 vs. 0.68\u00a0mmHg;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.029), and BMI (\u2212\u20090.45 vs. 0.00\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with T2DM and hypertension, the addition of henagliflozin to standard therapy over 6\u00a0months was associated with significant attenuation of adverse ventricular remodeling\u2014as evidenced by reductions in LVMI, left atrial diameter, and diastolic filling indices\u2014alongside clinically meaningful improvements in glycemic control, blood pressure, and body weight.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-026-03285-y","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:33:49Z","timestamp":1783740829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Henagliflozin attenuates adverse ventricular remodeling and improves cardiometabolic parameters in patients with type 2 diabetes and hypertension: real-world evidence from a propensity score-matched analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Nianfang","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuren","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"3285_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"3285_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41569-022-00829-z","volume":"20","author":"JG Wang","year":"2023","unstructured":"Wang JG, Zhang W, Li Y, et al. Hypertension in China: epidemiology and treatment initiatives. Nat Rev Cardiol. 2023;20(8):531\u201345.","journal-title":"Nat Rev Cardiol"},{"issue":"Suppl 5","key":"3285_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/dom.15764","volume":"26","author":"MR Weir","year":"2024","unstructured":"Weir MR. Cardiovascular risk reduction in type 2 diabetes: what the non-specialist needs to know about current guidelines. Diabetes Obes Metab. 2024;26(Suppl 5):14\u201324.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"3285_CR4","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2337\/dca24-0118","volume":"48","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Isasi CR, Al-Rousan T, et al. Associations of concurrent hypertension and type 2 diabetes with mortality outcomes: a prospective study of US. adults. Diabetes Care. 2025;48(7):1241\u201350.","journal-title":"Diabetes Care"},{"issue":"22","key":"3285_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"21","key":"3285_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"12","key":"3285_CR7","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"15","key":"3285_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3285_CR9","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association","year":"2025","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025. Diabetes Care. 2025;48(Suppl 1):S181\u2013206.","journal-title":"Diabetes Care"},{"issue":"3","key":"3285_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40261-015-0366-7","volume":"36","author":"X Yong","year":"2016","unstructured":"Yong X, Wen A, Liu X, et al. Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus. Clin Drug Investig. 2016;36(3):195\u2013202.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"3285_CR11","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.14314","volume":"23","author":"J Lu","year":"2021","unstructured":"Lu J, Fu L, Li Y, et al. Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Obes Metab. 2021;23(5):1111\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"3285_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-087617","volume":"14","author":"H Yan","year":"2024","unstructured":"Yan H, Wang W, Li Y, et al. Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open. 2024;14(8):e087617.","journal-title":"BMJ Open"},{"issue":"8","key":"3285_CR13","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/dom.14389","volume":"23","author":"J Weng","year":"2021","unstructured":"Weng J, Zeng L, Zhang Y, et al. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Obes Metab. 2021;23(8):1754\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"3285_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088687","volume":"15","author":"L Xu","year":"2025","unstructured":"Xu L, Wu Y, Li J, et al. Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis. BMJ Open. 2025;15(2):e088687.","journal-title":"BMJ Open"},{"issue":"16","key":"3285_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"7","key":"3285_CR16","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/dom.15586","volume":"26","author":"L Buttice","year":"2024","unstructured":"Buttice L, Ghani M, Suthakar J, et al. The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(7):2706\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"3285_CR17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022;146(18):1383\u2013405.","journal-title":"Circulation"},{"issue":"3","key":"3285_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen BL, Fletcher RA, Anker SD, et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA. 2026;335(3):233\u201344.","journal-title":"JAMA"},{"issue":"2","key":"3285_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.70021","volume":"18","author":"Q Ren","year":"2025","unstructured":"Ren Q, Tan Y, Zhang G, et al. Efficacy of hypoglycemic agents in metabolic dysfunction associated steatotic liver disease (MASLD): a systematic review and network meta-analysis. J Evid Based Med. 2025;18(2):e70021.","journal-title":"J Evid Based Med"},{"issue":"3","key":"3285_CR20","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/ehf2.14357","volume":"10","author":"M Moroney","year":"2023","unstructured":"Moroney M, Verma R, Hibino M, et al. Impact of diabetes duration on left ventricular mass regression with empagliflozin. ESC Heart Fail. 2023;10(3):2134\u201340.","journal-title":"ESC Heart Fail"},{"issue":"21","key":"3285_CR21","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140(21):1693\u2013702.","journal-title":"Circulation"},{"issue":"11","key":"3285_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1753-0407.13209","volume":"13","author":"D Kosugi","year":"2021","unstructured":"Kosugi D, Inaba H, Kaido Y, et al. Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus. J Diabetes. 2021;13(11):847\u201356.","journal-title":"J Diabetes"},{"issue":"4","key":"3285_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5543\/tkda.2024.27546","volume":"52","author":"E \u00c7elik","year":"2024","unstructured":"\u00c7elik E, Kerk\u00fctl\u00fco\u011flu M, \u015eahin M, et al. The impact of sodium-glucose cotransporter-2 inhibitors on atrial electromechanical conduction time. Turk Kardiyol Dern Ars. 2024;52(4):237\u201343.","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"1","key":"3285_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-025-02756-y","volume":"24","author":"A Ovchinnikov","year":"2025","unstructured":"Ovchinnikov A, Potekhina A, Filatova A, et al. Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial. Cardiovasc Diabetol. 2025;24(1):196.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"3285_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2459\/JCM.0000000000001523","volume":"24","author":"S Yu","year":"2023","unstructured":"Yu S, Sun Y, Wang N, et al. Effect of sodium-glucose cotransporter 2 inhibitors on left atrial remodeling and prognosis in patients with type 2 diabetes and heart failure with reduced ejection fraction. J Cardiovasc Med (Hagerstown). 2023;24(11):829\u201337.","journal-title":"J Cardiovasc Med (Hagerstown)"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03285-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03285-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03285-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:21:50Z","timestamp":1791246110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03285-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3285"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03285-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving human participants were reviewed and approved by the Institutional Review Board\/Ethics Committee of Hubei Provincial Third People\u2019s Hospital (Approval No. KY2025022). Written informed consent for participation was waived by the IRB\/ Ethics Committee due to the retrospective nature of the study and the use of anonymized\/de-identified clinical data, in accordance with national regulations and the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"297"}}